HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Michael A Badruddoja Selected Research

(131)I-ch81C6

6/2006Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Michael A Badruddoja Research Topics

Disease

4Glioblastoma (Glioblastoma Multiforme)
01/2018 - 12/2005
3Neoplasms (Cancer)
07/2007 - 10/2003
2Glioma (Gliomas)
06/2006 - 10/2004
1Weight Loss (Weight Reduction)
07/2007
1Central Nervous System Neoplasms
07/2007
1Gliosarcoma
10/2003

Drug/Important Bio-Agent (IBA)

2Bevacizumab (Avastin)FDA Link
01/2018 - 10/2017
2Temozolomide (Temodar)FDA LinkGeneric
01/2018 - 10/2017
2laromustine (VNP40101M)IBA
07/2007 - 01/2007
1Monoclonal AntibodiesIBA
06/2006
1(131)I-ch81C6IBA
06/2006
1Immunoglobulin G (IgG)IBA
06/2006
1Tyrosine Kinase InhibitorsIBA
12/2005
1Hydroxyurea (Hydrea)FDA LinkGeneric
12/2005
1Ribonucleotide Reductases (Ribonucleotide Reductase)IBA
12/2005
1Imatinib Mesylate (Gleevec)FDA Link
12/2005
1Adenosine Triphosphate (ATP)IBA
12/2005
1GadoliniumIBA
10/2004
1Dexamethasone (Maxidex)FDA LinkGeneric
10/2003
1Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
10/2003

Therapy/Procedure

1Aftercare (After-Treatment)
07/2007